

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :	A1	(11) International Publication Number: WO 96/22107 (43) International Publication Date: 25 July 1996 (25.07.96)
(21) International Application Number: PCT/GB96/00119		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 19 January 1996 (19.01.96)		
(30) Priority Data: 9501040.1 19 January 1995 (19.01.95) GB		
(71) Applicant (for all designated States except US): QUADRANT HOLDINGS CAMBRIDGE LIMITED [GB/GB]; Maris Lane, Trumpington, Cambridge CB2 2SY (GB).		
(72) Inventor; and		Published
(75) Inventor/Applicant (for US only): ROSER, Bruce, Joseph [GB/GB]; 4 Archway Court, Barton Road, Cambridge CB3 9LW (GB).		With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
(74) Agent: ABLEWHITE, Alan, James; Marks & Clerk, 57-60 Lincoln's Inn Fields, London WC2A 3LS (GB).		

(54) Title: DRIED BLOOD FACTOR COMPOSITION COMPRISING TREHALOSE

(57) Abstract

A stable blood factor composition contains a stabilising amount of trehalose in the absence of human serum albumin to provide a product stable at up to 60 °C.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

DRIED BLOOD FACTOR COMPOSITION COMPRISING TREHALOSE

This invention relates to dried compositions of blood factors for reconstitution with water or aqueous solutions.

Blood factors, particularly factor VIII and factor IX, are now the standard treatment for diseases caused by a lack of the appropriate factor, in particular haemophilia. The blood factor has generally been derived from human blood by various extraction techniques, for example as disclosed in EP-A-0083483, or by expression in genetically modified micro-organisms, for example as disclosed in EP-A-0160457 and EP-A-0182448.

Blood factor products such as factor VIII are highly delicate, unstable proteins. They are usually supplied in the form of frozen solutions in an appropriate buffer or, more generally, as freeze-dried powders. Even the freeze-dried powders must be kept cold during storage. In order to stabilise the freeze-dried material, commercial products contain a stabilising protein, in particular human serum albumin (HSA). It has not been thought possible to prepare a dry blood factor composition which is stable at ambient temperatures and at pasteurisation temperatures (e.g. 60°C) in the absence of HSA. However, the presence of HSA introduces considerable problems of purification since it is essential that the protein is free of viral contamination. The use of recombinant HSA to overcome these problems is expensive.

Trehalose is known to be a highly effective stabilising agent for delicate proteins, as disclosed in US-A-4891319, enabling proteins to be dried at temperatures above freezing. We have now found that if trehalose is used to stabilise a blood factor product, not only can the product be dried with or without freezing, but also the product is stable even when retained at a temperature of 60°C for an extended period, in the complete absence of HSA. According to the present invention therefore we provide a stable dried blood factor composition containing a stabilising amount of trehalose in the absence of albumin.

In general, any stabilising amount of trehalose may be used and an excess in general causes no problems. Indeed, the presence of trehalose aids the rehydration process and is physiologically acceptable for injection, being rapidly metabolised to glucose. The composition is particularly suited to formulations of factor VIII, which may also contain appropriate buffering and ion-reinforcing salts, in particular a source of calcium. In general, a ratio of about 1.0 to 1.5 mg of calcium ions per unit of factor VIII is appropriate.

Other buffering and modifying agents may also be present in the dried material for reconstitution to the injection solution, for example histidine. However, we have found that the level of salts, particularly sodium chloride, present can affect the preservation on drying. It is thought desirable for the commercial product for injection to have an isotonic salt concentration. However, the processing formulations which are freeze-dried

are desirably hypertonic, typically containing about 500 mM NaCl (isotonic NaCl = 150 mM), as this is considered to help stabilise the blood factor. As a result, commercial freeze-dried formulations generally have a high salt content and are reconstituted for injection with the appropriate amount of sterile water to obtain an isotonic solution.

A considerably reduced salt content is preferred for the dried material of the invention and, in general a solution of about 500 units of Factor VIII per ml to be dried should preferably contain less than 200 mM e.g. 75 to 150 mM, NaCl, especially about 100 mM, or even lower, e.g. 20 to 50 mM, especially about 22 to 30 mM. Low salt preparations possess a higher dry stability. The dried product can be reconstituted to the desired salt level with a saline solution instead of the conventional water. In general, the molar ratio of trehalose to salt should be above 1:1, especially above 2.5:1 e.g. above 10:1, preferably above 12.5:1.

The dried composition may be obtained by drying an appropriate solution of the blood factor containing the correct proportions of trehalose and other desired components. In general, the solution that is dried should simply contain all the components required in the reconstituted injection solution, although the solution for drying may not necessarily be at the same dilution. Typically, the solution for drying will contain from 1 to 1000 units of factor VIII per ml. The methods of drying may include freeze drying, vacuum drying and spray-drying. A particularly preferred method according to the invention comprises vacuum drying at a temperature no greater than 25°C, preferably no greater than 10°C, to form a foam, thus maximising the exposed surface and the drying effect.

The following examples illustrate the invention further.

Example 1

Recombinant factor VIII was received as a deep frozen solution containing approximately 2000 to 2500 units/ml in the manufacturer's high salt buffer. The thawed solution was dialysed against a buffer solution containing 500 mM NaCl, 15 mM CaCl₂ and 10 mM histidine at pH 6.8. The dialysed protein was diluted in the same buffer, but with added trehalose, to give a final concentration of 500 units per ml and 10% by weight trehalose at pH 6.8. This solution was vacuum dried in 1 ml aliquots. Vacuum was reduced step-wise from atmospheric to 4 Pa (30 mTorr) to avoid freezing the sample. The temperature of the sample was not allowed to rise above 12°C until the formation of a foam, after which the temperature was kept below 30°C. Total drying times were 24 to 28 hours.

The samples were stored for 0, 1.5, 3 and 6 months at 40°C and then reconstituted in 5 ml aliquots of sterile distilled water before being tested for activity. The results are shown in the following table in comparison with a commercial freeze-dried product containing HSA. Both the test and commercial samples have a high salt content. The post-drying results show that with trehalose it is possible to dry factor VIII successfully in the absence of HSA, but that a high salt content is unsatisfactory for long term storage, even in the presence of HSA.

Percentage of initial activity

Time (months)	Sample	Commercial Product
0	100.0	100.0
1.5	86.8	95.3
3	75.1	71.2
6	76.6	63.6

Example 2

Samples were dried as described in Example 1 but using a buffer formulation comprising 100 mM NaCl, 15 mM CaCl₂, 15mM histidine and 1.27 molar trehalose (48%) and stored at 60°C before reconstitution. The results are given in the following table, in which the activity is measured on an ACL 100 automated coagulometer (Instrumentation Laboratory SpA, Milan, Italy). The test sample, with a low salt content showed no significant loss of activity on storage, even after four weeks at 60°C.

Percentage of initial activity recovered

Wet control	100.0
Post-drying	95.5
Two weeks	96.0
Four weeks	96.8

Example 3

Two formulations were prepared containing different salt concentrations as shown:

Formulation A		Formulation B	
NaCl	0.13%	NaCl	1.03%
CaCl ₂	0.011%	CaCl ₂	0.011%
L-histidine	0.12%	L-histidine	0.12%
Tris	0.002%	Tris	0.002%
Tween 80	0.002%	Tween 80	0.002%
PEG 3350	0.004%	PEG 3350	0.004%
Trehalose	7.5%	Trehalose	7.5%
Factor VIII	50 U/ml	Factor VIII	50 U/ml
Water to 100%		Water to 100%	

10ml portions of the formulations were dispensed into separate 30ml vials so as to give a concentration of factor VIII of 500 units/vial.

Freeze-drying was performed in a Laconco (Lyph-lock 12 stoppering) freeze drier. Initially, the samples were cooled to -40°C and then placed under vacuum, before being warmed to -35°C. After 80 hours, the samples were warmed at a rate of 2.5°C/h until the shelf temperature reached 25°C. The samples were then kept at 25°C for two hours before being sealed under vacuum and removed from the drier.

After drying, the samples were rehydrated with 10ml of water and the concentration of factor VIII was measured twice (Assays 1 and 2). The results are given in the following table and are expressed as a percentage of the concentration of Factor VIII with respect to the prefill control (which had been frozen at -70°C). From the results shown, it can be concluded that Factor VIII can be successfully freeze dried in a trehalose based formulation in the absence of HSA.

Sample	Assay 1	Assay 2
Formulation A	77%	85%
Formulation B	91%	94%

CLAIMS

1. A stable dried blood factor composition containing a stabilising amount of trehalose in the absence of albumin.
2. A composition according to claim 1 containing 0.15 to 2.5 mg trehalose per unit of blood factor.
3. A composition according to claim 1 or claim 2 containing factor VIII.
4. A composition according to claim 3 containing 1.0 to 1.5 mg calcium ion per unit of factor VIII.
5. A composition according to any of claims 1 to 4 containing more than 2.5 moles trehalose per mole of salt.
6. A composition according to claim 5 containing more than 10 moles trehalose per mole of salt.
7. A method of preparing a composition according to any of claims 1 to 6, in which an aqueous solution of the blood factor containing trehalose is dried at a temperature no greater than 25°C.
8. A method according to claim 7, in which the solution is dried at a temperature no greater than 10°C.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 96/00119A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K38/37 A61K47/26

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 475 409 (LIFECCELL CORPORATION) 18 March 1992 see the whole document, especially claims 1-3, 7, 8-13 ---	1,3,7,8
X	BIOPHARM., vol. 4, no. 8, 1991, pages 47-53, XP000569065 B. ROSEN: "Trehalose drying: a novel replacement for freeze-drying" see the whole document, especially page 52, first paragraph ---	1,3,7,8 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *'A' document defining the general state of the art which is not considered to be of particular relevance
- *'E' earlier document but published on or after the international filing date
- *'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *'O' document referring to an oral disclosure, use, exhibition or other means
- *'P' document published prior to the international filing date but later than the priority date claimed

- *'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- *'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

- *'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

- *'&' document member of the same patent family

1

Date of the actual completion of the international search	Date of mailing of the international search report
3 May 1996	15.05.96
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+ 31-70) 340-3016	Authorized officer Orviz Diaz, P

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 96/00119

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J.L. CLELAND, EDITOR: "ACS Symposium Series 567. Formulation and Delivery of Proteins and Peptides." 1994, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC XP002002130 See Chapter 14, especially page 223, last paragraph ---	1,3,7,8
P,X	WO,A,95 07713 (BAXTER INTERNATIONAL INC.) 23 March 1995 see page 8, line 8-17 ---	1,3,7,8
Y	WO,A,87 00196 (QUADRANT BIORESOURCES LIMITED) 15 January 1987 see claims & US,A,4 891 319 cited in the application ---	1-8
Y	EP,A,0 314 095 (RORER INTERNATIONAL) 3 May 1989 see page 2, line 53 - page 3, line 25; claims ---	1-8
Y	EP,A,0 315 968 (RORER INTERNATIONAL) 17 May 1989 see page 2, line 52 - page 3, line 21; claims; examples 3-5 ---	1-8
P,Y	WO,A,95 01804 (PHARMACIA AB) 19 January 1995 see page 4, line 23 - page 6, line 8; claims; example 3 & SE,A,9 302 308 -----	1-8
Y		1-8

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB 96/00119

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-475409	18-03-92	AU-B-	6740594	22-09-94
		AU-B-	650045	09-06-94
		AU-B-	8379791	19-03-92
		CA-A-	2051092	13-03-92
		JP-A-	5126696	21-05-93
		US-A-	5336616	09-08-94
		US-A-	5364756	15-11-94
WO-A-9507713	23-03-95	AU-B-	7638094	03-04-95
WO-A-8700196	15-01-87	AU-B-	591160	30-11-89
		AU-B-	6136386	30-01-87
		DE-A-	3682047	21-11-91
		DK-B-	170173	06-06-95
		EP-A,B	0229810	29-07-87
		GB-A-	2187191	03-09-87
		JP-B-	7079694	30-08-95
		JP-T-	63500562	03-03-88
		US-A-	4891319	02-01-90
		CA-A-	1307485	15-09-92
EP-A-314095	03-05-89	AU-B-	2452088	04-05-89
		CA-A-	1329760	24-05-94
		DE-A-	3876600	21-01-93
		ES-T-	2053676	01-08-94
		JP-A-	1149733	12-06-89
EP-A-315968	17-05-89	US-A-	4877608	31-10-89
		AU-B-	2478888	11-05-89
		CA-A-	1329542	17-05-94
		DE-A-	3871334	25-06-92
		ES-T-	2042693	16-12-93
		JP-A-	1157917	21-06-89
		JP-B-	6076338	28-09-94
WO-A-9501804	19-01-95	AU-B-	6762794	06-02-95
		CA-A-	2163112	19-01-95
		SE-A-	9302308	06-01-95
		ZA-A-	9402035	05-01-95